Randomized clinical trials remain the gold standard for establishing a medication's effects, producing the evidence by which ...
MedPage Today on MSN
'Truly Practice Changing' Trial in Gastroesophageal Cancer
SAN FRANCISCO -- Incorporating the recently approved bispecific antibody zanidatamab (Ziihera) into first-line treatment for ...
A phase 3 study shows tafasitamab combined with lenalidomide and R-CHOP significantly improves outcomes for untreated DLBCL patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback